Charles River Labs pens digital pathology pact with Deciphex

Charles River
(Charles River)

CRO Charles River Laboratories has signed up to use a preclinical digital pathology “software-as-a-service” platform from Deciphex.

The deal, financials of which were not shared, sees Charles River Labs share with its clients Deciphex’s Patholytix Preclinical, its tech for developing a speedy workflow that allows pathologists to generate primary diagnostic or peer-review results from their computer workstation “faster than would be possible either with traditional microscopy processes or with stand-alone digital pathology software,” according to the firm.

RELATED: Charles River pens Takeda early-stage drugs deal

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Under the pact, the pair will also work together on deep-learning-enabled tools to support quicker pathology analytics. “By combining Deciphex’s unique digital pathology solutions with Charles River’s streamlined integrated drug discovery and development portfolio, Charles River clients will have access to an increasingly efficient, best-in-class platform,” the companies said in a joint statement.

“Our pathologists are the best in the industry—and in 2019, they examined over 4 million pathology slides. By providing them with the Deciphex solutions, we are giving them access to innovative tools that will provide valuable insights to clients earlier in the analysis phase,” said Birgit Girshick, corporate executive vice president at Charles River.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.